Susan Goodin, PharmD, FCCP, BCOP, associate director of clinical trials and therapeutics at The Cancer Institute of New Jersey (CINJ) has received the 2012 Award of Excellence from the Hematology/Oncology Pharmacy Association (HOPA). CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.
HOPA is a national professional organization dedicated to supporting hematology/oncology pharmacy practitioners in optimizing cancer patient care. The association recognized Dr. Goodin for making a significant, sustained contribution to hematology/oncology pharmacy and for providing leadership in supporting or improving this area.
Goodin, who is also a professor of medicine at UMDNJ-Robert Wood Johnson Medical School, leads CINJ's clinical trials program and since 1993 has served as director of CINJ's Division of Pharmaceutical Sciences. It is in this capacity that she oversees the pharmacy team that provides medications for patients and educates those patients about usage, pain management and other related aspects. An active researcher, Goodin also studies investigational drugs via clinical trials and promotes the importance of such study as a way to help researchers unlock the mysteries of cancer.
The Cranford resident is receiving the award at the association's 2012 annual meeting being held this week in Orlando.
Topical immunotherapy clears precancerous skin lesions and reduces cancer risk